Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin
- Sponsor
- Corporacion Parc Tauli
- Study ID
- NCT04829903
- Status
- Completed
Conditions
- Adolescent Obesity
- Obesity
- Type 2 Diabetes Treated With Insulin
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 19 Years
- Healthy Volunteers
- Not accepted
Interventions
- Dulaglutide — DRUGDulaglutide injections
- Liraglutide — DRUGLiraglutide injections
Study Details
To compare the efficacy and effect on glycemic control of Dulaglutide versus Liraglutide in obese Type 2 diabetic adolescents using metformin
Key Dates
- Start date
- Jan 2, 2020
- Status verified
- Mar 2022
- Primary completion
- Mar 29, 2021
- Completion
- Nov 20, 2021
Study Design
- Enrollment
- 116 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Group DULGroup taking Dulaglutide injections
- Placebo Comparator: Group LIRGroup taking Liraglutide injections
Primary Outcome Measure
Glycemic level [ Time Frame: 24 weeks for the duration of the study ]
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia